PDCD1 and neoplasm: First data from an ongoing phase 2 clinical trial confirmed that pembrolizumab plus ipilimumab regimen is tolerable and exerts anti-tumor activity in melanoma patients who have progressed after treatment with an anti-PD-1 mAb [90].